Treatment with AMG 337, a selective c-Met kinase inhibitor, led to a partial or near complete response in eight (62%) of 13 patients with MET-amplified gastroesophageal junction, gastric, or esophageal tumors [16]. This evidence concerns the gene MET and neoplasm of esophagus.